DOCSLIB.ORG

WHO Drug Information Vol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

WHO Drug Information Vol. 16, No. 1, 2002 World Health Organization WHO Drug Information Contents Vaccines and Biomedicines Hua Fo: unknown substance 26 Sibutramine safety review 26 International reference materials for Cyproterone with ethinylestradiol: risk of Creutzfeldt-Jakob disease 3 venous thromboembolism 27 WHO position on rabies vaccine 4 Alfa interferons: labelling change 27 Nefazodone: rare cases of liver failure 28 Safety Information Acarbose, zafirlukast and vincristine: WHO international drug monitoring: revised precautions 28 cerivastatin and gemfibrozil 8 Clozapine and myocarditis 28 International Conference on Harmonization Methotrexate: interactions 29 (ICH): pharmacovigilance activities 11 Stavudine: neuromuscular weakness 29 The COX-2 inhibitors 12 Recommended influenza virus vaccine Amiodarone and pulmonary toxicity 14 composition 29 Alendronate: link with pancreatitis? 14 Sodium phosphate oral solution: electrolyte Endocrinotoxicity induced by Coriandrum balance disturbance 30 sativa: a case report 15 Haemolysis after consumption of Viola tricolor 15 Lipodystrophy syndrome under-reported 16 Quality Assurance Issues WHO pilot pre-qualification project for pharmaceutical products: evaluation Current Topics of product files 31 Progress in pharmacogenetics and Access to HIV drugs and diagnostics 31 pharmacogenomics 17 List of pre-qualified products — 20 March 2002 32 Internet sales and reimbursement by insurance companies 20 Nevirapine: comments on HIVNET 012 from Recent Publications and Sources the manufacturer 21 Review of HIVNET 012 21 of Information Mother-to-child transmission of HIV: WHO WHO guidelines on stability testing 35 statement 22 WHO Model Formulary now available 35 Direct to consumer advertising 36 The information gap: new resource for Regulatory and Safety Action developing countries 36 Enoxaparin sodium injection: new safety warnings 23 Proposed International Ziprasidone hydrochloride: labelling 37 clarifications 23 Nonproprietary Names: List 86 Kava kava products and potential liver injury 24 Kava kava: investigations into liver injury 24 Rofecoxib interaction with warfarin 25 Recommended International Zolpidem and neurological reactions 25 81 Paroxetine: withdrawal symptoms 26 Nonproprietary Names: List 47 1 WHO Drug Information Vol. 16, No. 1, 2002 WHO Drug Information is now available at: http://www.who.int/druginformation 2 WHO Drug Information Vol. 16, No. 1, 2002 Vaccines and Biomedicines International reference materials Variant Creutzfeldt-Jakob Disease The number of human subjects incubating vCJD for Creutzfeldt-Jakob disease remains unknown and concern about the potential infectivity of their blood is affecting public health Transmissible spongiform encephalopathies (TSEs) policy on supply of blood products in several coun- include bovine spongiform encephalopathy (BSE) in tries. As is the case for CJD, there has been no cattle, scrapie in sheep, and Creutzfeldt-Jakob evidence of transmission of vCJD by blood or blood disease (CJD) in humans. TSEs are characterized components or plasma-derived products. vCJD is by spongiform degeneration of the brain and the however a new emerging disease and the risk is transformation of the normal form of a ubiquitous unknown. protein termed prion protein, PrPc, into an abnormal sc sc isoform, PrP . PrP is the only marker of the Although novel antibodies and new applications of disease. existing technologies have been developed as Concern has been generated following the appear- promising approaches for diagnostic procedures for ance of a variant Creutzfeldt-Jakob (vCJD) disease vCJD, they are at a relatively early stage of devel- in the United Kingdom linked to bovine spongiform opment. Pre-mortem clinical diagnosis of vCJD by encephalopathy (BSE) and action has been taken magnetic resonance imaging (MRI) seems to be to reduce channels of transmission. Cases of vCJD reliable. However, diagnosis during the asympto- have now reached 130 internationally — raising the matic incubation period is not yet possible and a profile of this class of disease as a risk to human reliable diagnostic method based on easily accessi- health. ble samples, such as serum, is indispensable. There is also a need for independent comparison of Sporadic, familial and iatrogenic the various laboratory approaches to diagnosis. Creutzfeldt-Jakob disease The accurate diagnosis of CJD is currently based WHO International Reference Materials on postmortem histopathological examination of the The availability of reliable diagnostic procedures brain or immunohistopathology, which adds an would allow the detection of asymptomatic subjects extra level of certainty when appropriate antibodies during the long periods of incubation of CJD and and techniques are used. Pre-mortem diagnosis vCJD. Panels of reference materials of various remains problematic and is limited to detection kinds need to be built up to compare the effective- through clinical features or electroencephalo- ness of new in vitro and in vivo assay systems sc graphic (EEG) findings. No validated preclinical using animal models and relate detection of PrP diagnostic tests are currently available for the and infectivity. Comparability of levels of detection detection of PrPsc. of TSE agents by different methods will only be possible through the availability of these prepara- Bovine spongiform encephalopathy tions. Decisions concerning the safety of pharma- Methods for the accurate diagnosis of pre-or post- ceuticals and blood products can then be taken mortem BSE which may be applied on a large scale based on scientific findings and would considerably to the examination of animals either at or prior to strengthen precautionary measures implemented slaughter, would have major epidemiological impli- by medicines regulatory authorities. cations in minimising the risk of infection to other animals or to humans through food or biological The need to develop a panel of international refer- materials used in the production of medicinal prod- ence materials for the diagnosis and study of ucts. ELISA and Western Blot testing of brain transmissible spongiform encephalopathies (TSEs) tissues can already be used to detect some pre- for validation of CJD and vCJD diagnostic proce- clinical cases postmortem. No ante-mortem diag- dures and for the comparison of methods was first nostic methods suitable for testing live asympto- discussed during a WHO Consultation held in 1999. matic animals during the incubation period of BSE A WHO Working Group on International Reference are available. Materials for Diagnosis and Study of TSEs was 3 Vaccines and Biomedicines WHO Drug Information Vol. 16, No. 1, 2002 established to identify needs and priorities for the will benefit public health internationally, and WHO production of international reference materials and will offer these materials as calibrants to laborato- development of a WHO repository. The develop- ries seeking to optimize a variety of in vitro and in ment of human brain-derived materials as candi- vivo diagnostic procedures for TSEs. date biological reference materials to compare the sensitivity of assays for CJD and vCJD is now Development of brain derived materials from cattle under way. Four human brain-derived with bovine spongiform encephalopathy (BSE) and homogenates have been prepared from: from sheep with both BSE and scrapie infections will also be addressed in collaboration with the • uninfected brain; Organisation International des Epizooties (OIE). • sporadic CJD brain type 1 (sp1CJD); References • sporadic CJD brain type 2 (sp2CJD); and • variant CJD brain (vCJD). 1. Information on the WHO Working Group on Interna- tional Reference Materials for Diagnosis and Study of Thirteen international laboratories will characterize TSEs: http://www.who.int/biologicals these materials and work on in vitro assays of PrPsc content. The brain samples which have been 2. World Health Organization. Report of a WHO Consulta- provided for analysis cover all PrPsc types de- tion on Medicinal and other Products in Relation to Human scribed. These samples have also been distributed and Animal Transmissible Spongiform Encephalopathies. to twelve laboratories to perform Western immuno- Geneva, Switzerland, 24–26 March 1997. blot tests according to agreed protocols. Informa- 3. World Health Organization. Report on a WHO Consul- tion from these activities will be fundamental in tation on Diagnostic Procedures for Transmissible Spongi- confirming their suitability for development as form Encephalopathies (TSEs): Need for Reference International Reference Materials. A WHO directed Reagents and Reference Panels. Geneva, Switzerland, study of the Terminology of Human PrPsc types and 22–23 March 1999. subtypes is also being carried out to resolve the current disparity in the literature on the existence of 4. World Health Organization. Report on a Working Group distinct human PrPsc types associated with sporadic on International Reference Materials for Diagnosis and or acquired CJD. Study of Transmissible Spongiform Encephalopathies (TSEs). Geneva, Switzerland, 21–22 September 1999. Results from the in vitro studies were analysed at a 5. World Health Organization. Report on International meeting of the WHO Working Group on Interna- Reference Materials for Diagnosis and Study of Transmis- tional Reference Materials for Diagnosis and Study sible Spongiform Encephalopathies (TSEs). Geneva, of TSEs in April 2002. Results from laboratories Switzerland, 25–26 May 2000. using different modifications
Recommended publications
  • Enoxaparin Sodium Solution for Injection, Manufacturer's Standard

    Enoxaparin Sodium Solution for Injection, Manufacturer's Standard

    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrLOVENOX® Enoxaparin sodium solution for injection 30 mg in 0.3 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 40 mg in 0.4 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 60 mg in 0.6 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 80 mg in 0.8 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 100 mg in 1 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 300 mg in 3 mL solution (100 mg/mL), multidose vials for subcutaneous or intravenous injection PrLOVENOX® HP Enoxaparin sodium (High Potency) solution for injection 120 mg in 0.8 mL solution (150 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 150 mg in 1 mL solution (150 mg/mL), pre-filled syringes for subcutaneous or intravenous injection Manufacturer’s standard Anticoagulant/Antithrombotic Agent ATC Code: B01AB05 Product Monograph – LOVENOX (enoxaparin) Page 1 of 113 sanofi-aventis Canada Inc. Date of Initial Approval: 2905 Place Louis-R.-Renaud February 9, 1993 Laval, Quebec H7V 0A3 Date of Revision September 7, 2021 Submission Control Number: 252514 s-a version 15.0 dated September 7, 2021 Product Monograph – LOVENOX (enoxaparin) Page 2 of 113 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. TABLE OF CONTENTS ..............................................................................................................
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES

    Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies

    Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies

    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
  • (12) United States Patent (10) Patent No.: US 9,375.433 B2 Dilly Et Al

    (12) United States Patent (10) Patent No.: US 9,375.433 B2 Dilly Et Al

    US009375433B2 (12) United States Patent (10) Patent No.: US 9,375.433 B2 Dilly et al. (45) Date of Patent: *Jun. 28, 2016 (54) MODULATORS OF ANDROGENSYNTHESIS (52) U.S. Cl. CPC ............. A6 IK3I/519 (2013.01); A61 K3I/201 (71) Applicant: Tangent Reprofiling Limited, London (2013.01); A61 K3I/202 (2013.01); A61 K (GB) 31/454 (2013.01); A61K 45/06 (2013.01) (72) Inventors: Suzanne Dilly, Oxfordshire (GB); (58) Field of Classification Search Gregory Stoloff, London (GB); Paul USPC .................................. 514/258,378,379, 560 Taylor, London (GB) See application file for complete search history. (73) Assignee: Tangent Reprofiling Limited, London (56) References Cited (GB) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this 5,364,866 A * 1 1/1994 Strupczewski.......... CO7C 45/45 patent is extended or adjusted under 35 514,254.04 U.S.C. 154(b) by 0 days. 5,494.908 A * 2/1996 O’Malley ............. CO7D 261/20 514,228.2 This patent is Subject to a terminal dis 5,776,963 A * 7/1998 Strupczewski.......... CO7C 45/45 claimer. 514,217 6,977.271 B1* 12/2005 Ip ........................... A61K 31, 20 (21) Appl. No.: 14/708,052 514,560 OTHER PUBLICATIONS (22) Filed: May 8, 2015 Calabresi and Chabner (Goodman & Gilman's The Pharmacological (65) Prior Publication Data Basis of Therapeutics, 10th ed., 2001).* US 2015/O238491 A1 Aug. 27, 2015 (Cecil's Textbook of Medicine pp. 1060-1074 published 2000).* Stedman's Medical Dictionary (21st Edition, Published 2000).* Okamoto et al (Journal of Pain and Symptom Management vol.
  • Antibody Drug Conjugate Development in Gastrointestinal Cancers: Hopes and Hurdles from Clinical Trials

    Antibody Drug Conjugate Development in Gastrointestinal Cancers: Hopes and Hurdles from Clinical Trials

    Wu et al. Cancer Drug Resist 2018;1:204-18 Cancer DOI: 10.20517/cdr.2018.16 Drug Resistance Review Open Access Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials Xiaorong Wu, Thomas Kilpatrick, Ian Chau Department of Medical oncology, Royal Marsden Hospital NHS foundation trust, Sutton SM2 5PT, UK. Correspondence to: Dr. Ian Chau, Department of Medical Oncology, Royal Marsden Hospital NHS foundation trust, Downs Road, Sutton SM2 5PT, UK. E-mail: [email protected] How to cite this article: Wu X, Kilpatrick T, Chau I. Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials. Cancer Drug Resist 2018;1:204-18. http://dx.doi.org/10.20517/cdr.2018.16 Received: 31 Aug 2018 First Decision: 8 Oct 2018 Revised: 13 Nov 2018 Accepted: 16 Nov 2018 Published: 19 Dec 2018 Science Editors: Elisa Giovannetti, Jose A. Rodriguez Copy Editor: Cui Yu Production Editor: Huan-Liang Wu Abstract Gastrointestinal (GI) cancers represent the leading cause of cancer-related mortality worldwide. Antibody drug conjugates (ADCs) are a rapidly growing new class of anti-cancer agents which may improve GI cancer patient survival. ADCs combine tumour-antigen specific antibodies with cytotoxic drugs to deliver tumour cell specific chemotherapy. Currently, only two ADCs [brentuximab vedotin and trastuzumab emtansine (T-DM1)] have been Food and Drug Administration approved for the treatment of lymphoma and metastatic breast cancer, respectively. Clinical research evaluating ADCs in GI cancers has shown limited success. In this review, we will retrace the relevant clinical trials investigating ADCs in GI cancers, especially ADCs targeting human epidermal growth receptor 2, mesothelin, guanylyl cyclase C, carcinogenic antigen-related cell adhesion molecule 5 (also known as CEACAM5) and other GI malignancy specific targets.
  • Study Protocol: LPCN 1021-18-001

    Study Protocol: LPCN 1021-18-001

    Oral Testosterone Undecanoate Protocol No. LPCN 1021-18-001 Lipocine Inc. TU, LPCN 1021 675 Arapeen Drive, Suite 202 Salt Lake City, UT-84108 1.0 TITLE PAGE Clinical Study Protocol: LPCN 1021-18-001 Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men. Investigational Product : Testosterone Undecanoate (TU, LPCN 1021) Date of Protocol : 19 February 2019 FDA IND No. : 106476 Development Phase : Phase 3 Testosterone replacement therapy in adult, 18 years or older, males for conditions associated with a deficiency or absence of endogenous Indication : testosterone – primary hypogonadism (congenital or acquired) or secondary hypogonadism (congenital or acquired) Investigator : Multi-Center, US Sponsor : Lipocine Inc. 675 Arapeen Drive, Suite 202, Salt Lake City, Utah – 84108 Tel: +1-801-994-7383 Fax: +1-801-994-7388 Sponsor / : Nachiappan Chidambaram Emergency Contact 675 Arapeen Drive, Suite 202, Salt Lake City, Utah – 84108 Tel: +1-801-994-7383, Ext 2188 Fax: +1-801-994-7388 Email: [email protected] Protocol Version : 06 Confidentiality Statement This document is a confidential communication of Lipocine Inc. Acceptance of this document signifies agreement by the recipient that no unpublished information contained within will be published or disclosed to a third party without prior written approval, except that this document may be disclosed to an Institutional Review Board under the same conditions of confidentiality. Date: 19 February 2019 Confidential Page 1 of 50 Oral Testosterone Undecanoate Protocol No. LPCN 1021-18-001 Lipocine Inc. TU, LPCN 1021 675 Arapeen Drive, Suite 202 Salt Lake City, UT-84108 2.0 SUMMARY OF CHANGES TO PROTOCOL VERSION 2 Version 02 of the LPCN 1021-18-001 study protocol was developed to make the following changes to the study: • Added sexual desire and sexual distress questions to pre-treatment and post-treatment phases of the study.
  • The Evaluation of Drug Regulation - Economic Approaches Into the Valuation and Evaluation of the Drug Regulatory Framework

    The Evaluation of Drug Regulation - Economic Approaches Into the Valuation and Evaluation of the Drug Regulatory Framework

    The Evaluation of Drug Regulation - Economic approaches into the valuation and evaluation of the drug regulatory framework Jacoline Bouvy The evaluation of drug regulation – Economic approaches into the valuation and evaluation of the drug regulatory framework Bouvy, JC. ISBN 000000 Author Jacoline Bouvy Cover photo Bigstock.com Printed by Drukkerij Mostert en Van Onderen! The evaluation of drug regulation – Economic approaches into the valuation and evaluation of the drug regulatory framework Evaluatie van geneesmiddelenregulering – Economische toepassingen in de waardering en evaluatie van het regulatoire geneesmiddelensysteem (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op woensdag 23 januari 2013 des middags te 12.45 uur door Jacoline Catharina Bouvy geboren op 27 maart 1985 te Rotterdam Promotor: Prof. dr. H. Schellekens Co-promotor: Dr. M.A. Koopmanschap The studies presented in this thesis were performed in the context of the Escher project (T6- 202), a project of the Dutch Top Institute Pharma. ‘It is our choices, Harry, that show what we truly are, far more than our abilities.’ Albus Dumbledore (In J.K. Rowling’s Harry Potter and the Chamber of Secrets) Glossary ADR Adverse drug reaction CBG-MEB Dutch Medicines Evaluation Board CKD Chronic Kidney Disease DCE Discrete Choice Experiment DHPC Direct Healthcare
  • Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After Hip

    Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After Hip

    International Journal of Orthopaedics Sciences 2020; 6(3): 90-95 E-ISSN: 2395-1958 P-ISSN: 2706-6630 IJOS 2020; 6(3): 90-95 Rivaroxaban versus enoxaparin for © 2020 IJOS www.orthopaper.com thromboprophylaxis after hip arthroplasty Received: 20-05-2020 Accepted: 22-06-2020 Dr. Lenin Ligu and Dr. Moji Jini Dr. Lenin Ligu Assistant professor. Tomo Riba Institute of Health and Medical DOI: https://doi.org/10.22271/ortho.2020.v6.i3b.2183 Sciences (TRIHMS), Arunachal Pradesh, India Abstract Background: Introduction: Total hip arthroplasty (THA) is a successful surgical procedure for reducing Dr. Moji Jini pain and improving physical function in osteoarthritis. It is one of the most effective orthopaedic Director, Tomo Riba Institute of procedures. Health and Medical Sciences, Material and methods: Patients were eligible for the study if they were aged 18 years or older and were Arunachal Pradesh, India scheduled for total hip arthroplasty. Patients were ineligible if they were scheduled to undergo staged, bilateral hip arthroplasty were pregnant or breastfeeding, had active bleeding or a high risk of bleeding, or any disorder contraindicating the use of Rivaroxaban/enoxaparin that might necessitate enoxaparin dose adjustment. Results: Of the 52 patients enrolled in study, 52 patients were randomized to receive either Rivaroxaban (n=26) or enoxaparin (n=26). The baseline demographic characteristics of the two randomized treatment groups are well balanced as described in Table 1. The surgical characteristics are described in Table 2. Conclusion: Rivaroxaban, given as a once-daily 10 mg fixed dose 6–8 h postoperatively, is the first new oral anticoagulant to significantly reduce the incidence of venous thromboembolism after total knee arthroplasty, compared with enoxaparin 30 mg twice daily, starting 12–24 h postoperatively, without a significant difference in the risk of major or clinically relevant bleeding.
  • (12) United States Patent (10) Patent No.: US 9.498,544 B2 Ennis Et Al

    (12) United States Patent (10) Patent No.: US 9.498,544 B2 Ennis Et Al

    USOO949854.4B2 (12) United States Patent (10) Patent No.: US 9.498,544 B2 Ennis et al. (45) Date of Patent: Nov. 22, 2016 (54) GENETICALLY MODIFIED HUMAN (56) References Cited UMIBILICAL CORD PERVASCULAR CELLS FOR PROPHYLAXIS AGAINST OR U.S. PATENT DOCUMENTS TREATMENT OF BIOLOGICAL, OR 5,158,867 A 10/1992 McNally et al. CHEMICAL AGENTS 5,919,702 A 7/1999 Purchio et al. 6,132,724 A 10/2000 Blum (71) Applicant: Tissue Regeneration Therapeutics 7,122,178 B1 10/2006 Simmons et al. 7,547,546 B2 6/2009 Davies et al. Inc., Toronto (CA) 2003.0161818 A1 8, 2003 Weiss et al. 2004/O136967 A1 7/2004 Weiss et al. 2004/O137612 A1 7/2004 Baksh et al. (72) Inventors: Jane Elizabeth Ennis, Oakville (CA); 2005/OO 19911 A1 1/2005 Gronthos et al. Jeffrey Donald Turner, 2005, 0148074 A1 7/2005 Davies et al. Chute-a-Blondeau (CA); John Edward 2005/O158289 A1 7/2005 Simmons et al. Davies, Toronto (CA) 2005/0281790 A1 12/2005 Simmons et al. 2006, OOO8452 A1 1/2006 Simmons et al. 2006, O193840 A1 8, 2006 Gronthos et al. (73) Assignee: Tissue Regeneration Therapeutics 2006, O199263 A1 9/2006 Auger et al. Inc., Toronto (CA) 2006/0286O77 A1 12/2006 Gronthos et al. 2007/0134205 A1 6/2007 Rosenberg 2008.0020459 A1 1/2008 Baksh et al. (*) Notice: Subject to any disclaimer, the term of this 2008.0113434 A1 5/2008 Davies et al. patent is extended or adjusted under 35 2009/0047277 A1 2/2009 Reed et al.
  • Tanibirumab (CUI C3490677) Add to Cart

    Tanibirumab (CUI C3490677) Add to Cart

    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al

    (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al

    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
  • American College of Epidemiology Annual Meeting Abstracts, September 7-10, 2019, Pasadena, California

    American College of Epidemiology Annual Meeting Abstracts, September 7-10, 2019, Pasadena, California

    Annals of Epidemiology 36 (2019) 66e78 Contents lists available at ScienceDirect Annals of Epidemiology journal homepage: www.annalsofepidemiology.org American College of Epidemiology Annual Meeting Abstracts, September 7-10, 2019, Pasadena, California Oral Presentations Exploring uniformity of gestational diabetes Methods: We estimated the percentage of overdose deaths reported in the screening and diagnosis using real-world National Vital Statistics System with missing toxicology results from 2010- ’ electronic health record data 2016, overall and by decedents demographic and geographic characteristics. We used a multi-level model to evaluate prevalence of missingness by decedent characteristics, accounting for geographic clustering. & J.M. Lawrence, X. Li. Department of Research Evaluation, Kaiser Results: One-fifth of 351,345 drug overdose deaths from 2010-2016 did not Permanente Southern California, Pasadena, CA indicate a specific drug, declining from 24.4% in 2010 to 14.6% in 2016. In a multi-level model controlling for all predictors, deaths were less likely to Purpose: Gestational diabetes (GDM) surveillance frequently relies on In- have missing information if they occurred in metro counties compared to ternational Classification of Disease (ICD) codes to identify cases. GDM di- rural counties (aOR: 0.31, 95%CI: 0.24, 0.41) and in counties with medical agnoses can be based on several criteria including Carpenter & Coustan examiners versus coroners (aOR: 0.57, 95%CI: 0.47, 0.69). Male decedents (C&C) and International Association of Diabetes in Pregnancy Group were less likely to have missing information than females (aOR: 0.73, 95% (IADPSG). Our objectives were to describe GDM testing patterns within one CI: 0.69, 0.77), and non-Hispanic whites were more likely to have missing large health system and evaluate how well diagnostic coding corresponds information than non-Hispanic blacks (aOR: 1.31, 95%CI: 1.2, 1.4).